

Sterile Compounding Boot Camp®

Best Practices for Handling Hazardous Drugs



All times Eastern	Activity Title and Objectives (with CE information)
DAY 1 – All times Eastern	
9:00–9:30 AM	■ Introduction
9:30–10:30 AM	■ Overview of USP 800 and HD Handling for Sterile and Nonsterile Compounding <ul style="list-style-type: none"> • Cite examples of HD-exposure effects on persons who handle HDs. • Describe the location of resources regarding HD practice. • Recall common HD guidelines, standards, and regulatory best practice events. • List the major elements of USP 800. • Differentiate between the scope of USP Chapters 795, 797, and 800. • Describe the current issues related to USP Compounding Chapter enforceability and compendial applicability. <p><i>ACPE UAN: JA0006454-0000-22-3040-L07-P/T; 1 credit hours; application-based</i></p>
10:30–10:45 AM	■ Break
10:45 –11:30 AM	■ Assessment of Risk for Sterile and Nonsterile HD Compounding <ul style="list-style-type: none"> • List which drugs may be exempted from full containment and work practices of USP 800. • Define the components required in an AoR. • Evaluate different approaches to the creation and maintenance of an AoR. • Discuss specific examples of AoR strategies from actual practice. <p><i>ACPE UAN: JA0006454-0000-22-3043-L07-P/T; 0.75 credit hours; knowledge-based</i></p>
11:30 AM –12:30 PM	■ C-SECs for Sterile and Nonsterile Hazardous Drug Compounding <ul style="list-style-type: none"> • Describe the types of compliant C-SECs for nonsterile and sterile HD compounding. • Discuss considerations relevant to the use of pass-throughs in HD applications. • Analyze the allowable but suboptimal design of C-SECs and strategies used to compensate for such. • Describe the tests required for certification of C-SECs. <p><i>ACPE UAN: JA0006454-0000-22-3046-L07-P/T; 1 credit hours; application-based</i></p>
12:30–1:15 PM	■ Lunch
1:15–2:00 PM	■ C-PECs for Sterile and Nonsterile Hazardous Drug Compounding <ul style="list-style-type: none"> • Describe the types of compliant C-PECs for nonsterile and sterile HD compounding. • Describe the tests required for certification of C-PECs. <p><i>ACPE UAN: JA0006454-0000-22-3047-L07-P/T; 0.75 credit hours; knowledge-based</i></p>
2:00–2:30 PM	■ Response to HD Exposure and Spills (USP 795 and 797) <ul style="list-style-type: none"> • List the required elements of an exposure-control and response plan. • Discuss the requirements for HD spill cleanup. • Describe the logistical and practical hurdles that can be encountered in implementing an effective spill management program. • List potential strategies for effective spill management. <p><i>ACPE UAN: JA0006454-0000-22-3042-L07-P/T; 0.5 credit hours; knowledge-based</i></p>
2:30–2:45 PM	■ Break



2:45–3:45 PM	<p>■ Donning, Doffing, and PPE for Sterile and Nonsterile HD Compounding</p> <ul style="list-style-type: none"> • List the best sequence in which to perform donning and doffing of HD PPE resulting in microbial protection of CSPs, HD containment, and protection of the worker. • Differentiate between USP 800 requirements and CriticalPoint best practice recommendations. • Evaluate proper donning and doffing practices. • Identify garbing-technique best practices to reduce HD contamination. <p><i>ACPE UAN: JA0006454-0000-22-3039-L07-P/T; 1 credit hours; application-based</i></p>
3:45–4:45 PM	<p>■ USP 800 Sterile Compounding Work Practice Strategies</p> <ul style="list-style-type: none"> • List the practice elements essential to reducing the generation of HD contamination and risk of exposure throughout the HD-use lifespan. • Differentiate between the USP 800 requirements and CriticalPoint best practice recommendations. • Describe effective handling during compounding to ensure the final HD CSP container and packaging are free from HD contamination. • Evaluate safe transport procedures for HD inventory and final CSPs. <p><i>ACPE UAN: JA0006454-0000-22-3044-L07-P/T; 1 credit hours; application-based</i></p>
4:45–5:15 PM	<p>■ Wipe Sampling and CSTDs for Sterile and Nonsterile Hazardous Drug Compounding</p> <ul style="list-style-type: none"> • Differentiate USP 800 wipe sampling recommendations from CriticalPoint best practice recommendations. • List the wipe sampling methods available on the market. • Identify potential wipe sampling locations and the frequency of sampling. • Discuss the types of CSTDs available for use in compounding and administration. • Evaluate the efficacy of CSTDs using appropriate references. <p><i>ACPE UAN: JA0006454-0000-22-3036-L07-P/T; 0.5 credit hours; knowledge-based</i></p>
5:15–5:30 PM	<p>■ Summary</p>

DAY 2 – All times Eastern

9:00–10:00 AM	<p>■ Lab: Doffing of HD Garb and Negative-Pressure Sterile Compounding</p> <ul style="list-style-type: none"> • Perform the best practice doffing HD PPE. • Give examples of the importance of using coated gowns and waterproof shoe covers in HD compounding environments. • Contrast positive- and negative-pressure compounding with using a CSTD, and list the challenges associated with each compounding strategy. • Compare the time necessary to correctly perform negative-pressure compounding with the use of supplemental engineering controls at your location. • Identify appropriate negative-pressure compounding techniques used by compounding personnel. <p><i>ACPE UAN: JA0006454-0000-22-3037-L07-P/T; 1 credit hours; application-based</i></p>
10:00–11:00 AM	<p>■ Decontamination and Cleaning in HD Environments (USP 795 and 797)</p> <ul style="list-style-type: none"> • Define and differentiate the terms deactivation, decontamination, cleaning, disinfection, and sanitization. • Identify agents that may be used for decontamination of hazardous drugs. • Properly sequence decontamination, cleaning and disinfection, and application of sterile IPA in HD environments.



	<ul style="list-style-type: none"> Identify opportunities to modify decontamination, cleaning, and disinfection practices to ensure removal/containment of HD residue without compromising the state of microbial control. <p><i>ACPE UAN: JA0006454-0000-22-3041-L07-P/T; 1 credit hours; application-based</i></p>
11:00–Noon	<p>Lab: What’s Wrong with this Picture (USP 795, 797, and 800)</p> <ul style="list-style-type: none"> Evaluate design concerns relative to USP 797 and 800 compliance. Give examples of best practice USP 800 work practices. <p><i>ACPE UAN: JA0006454-0000-22-3045-L07-P/T; 1 credit hours; application-based</i></p>
Noon–12:30 PM	<p>Summary</p>

This program also requires the following self-study courses as pre-course work (will be added to your CriticalPoint LMS account after registration):

Requirements and Best Practices for Hazardous Drug Compounding (5 courses/each with 1 hour CE)

- Hazardous Drug Overview
- Containment Primary and Secondary Engineering Controls (USP 795 and 797)
- Personal Protective Equipment for HD Handling for USP 795 and 797 Compounding
- HD Work Practice: Receiving through Transport to Patients
- HD Work Practice: Decontamination and Spill Management (USP 795 and 797)



In support of improving patient care, TRC Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Statement of Participation/Course Completion

Credit will be awarded to participants who attend the course, submit a course evaluation within 20 days of the date of participation, and have provided an accurate NABP e-Profile ID and DOB. Participants who have successfully completed this course AND have provided accurate NABP e-Profile information, including month and day of birth, will have their CE credits submitted to CPE Monitor.

Florida-licensed pharmacists and pharmacy technicians: Course completions will be reported to CE Broker if the participant has successfully fulfilled all course completion requirements AND has provided the name and license number that matches what is on file with the Florida Board of Pharmacy. If this information is not provided within 20 days of the date of the activity, the participant will be responsible for manually uploading their completion to CE Broker.

It is the participant’s responsibility to verify credit is accurately posted to CPE Monitor and CE Broker (if applicable). Participants who have questions about their credit or do not see their credit on CPE Monitor (or CE Broker if applicable) 20 days after their participation should [contact TRC](#). Requests received after day 30 may not receive credit. Official statements of credit are only available from [CPE Monitor](#).

Credit for a specific course can only be awarded a single time. If you have previously completed a course as part of another program, you will only receive credit the first time the course is completed.

Target Learners: This activity is intended for pharmacists and pharmacy technicians in any practice setting.



Disclosure

The editors of this activity and its publisher, TRC Healthcare (TRC), have no relevant financial interests related to the products or services covered by this activity. TRC does not receive any commercial support and does not accept any advertising for its educational activities. It is completely independent and is supported entirely by subscriptions. In support of ACCME's Standards for Integrity and Independence, individuals declaring financial relationships with commercial interests (ineligible companies) are detailed below. When no financial relationship is listed, the individual has nothing to disclose. All relevant financial relationships, when present, have been mitigated. TRC focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers. Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical or legal judgments. Information and Internet links in this activity were current as of the date of release.

CriticalPoint/TRC Healthcare Faculty, Editors, & Staff

Tammie Armeni, RPh, PharmD

Vice President, Content Management & Accreditation

Trish Cipoletti

Quality Control Manager

Latousha Jackson, PharmD, BCPS, BCSCP

Editor

Adam West, RCCP-SCF, NSF-49 accreditation

Environmental Monitoring and Training Specialist

Colene West

Continuing Education Content Supervisor

Cost

The fee for this activity is available online. Register at <https://www.criticalpoint.info/activities>

Software/Hardware Requirements

TRC makes every effort to test and support the most recent version. This activity can be viewed on any device with an internet connection using one of the following browsers:

- Google Chrome, most recent stable version. No configuration recommendations.
- Mozilla Firefox, most recent stable version. No configuration recommendations.
- Apple Safari, most recent stable version. No configuration recommendations.

NOTE: For all browsers, you must have JavaScript and cookies enabled. To view PDFs, you will need a PDF-capable browser or standalone PDF viewer.

Your Privacy

In order to provide you with continuing education, Therapeutic Research obtains information such as your name, address, email address, phone number, payment information, etc. We treat this information as confidential and use it to provide you with the best service possible. Therapeutic Research has NEVER released any of this information to any outside organization for such organization's own commercial or marketing use and has a policy against doing so. We do not engage in renting out, selling, or trading names of subscribers or any information about any subscriber.

To provide you with valuable services, we will occasionally employ third parties to meet your needs. In such cases, only the information needed to meet your need will be shared with the outside organization. Therapeutic



Research only employs third parties that have similarly protective privacy policies. We do not allow any other organization to send you unsolicited emails about any products or services. We might send you information about your subscription, your continuing education credits, or our own drug information services. We do not gather data or track your web usage of any websites other than our own. For further information see our Privacy Policy or submit a request at <http://info.therapeuticresearch.com/privacyofficer>.